alxn1820
mAbexperimentalMulti-specific
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2020 (NCT04631562)
Timeline
Indications
Mechanism of action
- ProperdinINHIBITOR
CFP inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5315009 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07160608 | Phase 2 | Oct 31, 2025 | Alexion |
| NCT05565092 | Phase 2 | Dec 1, 2022 | Alexion |
| NCT04631562 | Phase 1 | Dec 31, 2020 | Alexion, Syneos Health |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alexion | For profit | 3 | 3 | 2 | 2020 |
| Syneos Health | For profit | 1 | 0 | 1 | 2020 |
2 organizations
Page 1 / 1